For research use only. Not for therapeutic Use.
Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015)[1][2][3][4].
Fluocinolone (0.1-50 μg/mL, 2 days) improves foam cell survival in THP-1 cells[1].
Fluocinolone (0.1-50 μg/mL, 2 days) inhibits infammatory cytokines secretion and reduces cholesteryl ester accumulation[1].
Fluocinolone (0.1-100 μmol/L, 24 h) promotes the proliferation of DPCs[2].
Fluocinolone (1-10 μmol/L, 7 days) promotes the expressions of BSP, OCN, DSPP, and Wnt4, and up-regulates Wnt4 and the dentin-specific marker dentin sialophosphoprotein[2].
Fluocinolone (500 μg/kg, Intraperitoneal injection, once a day for 2 weeks) prevents development of significant peripheral neuropathy in a mouse model of PTX-induced[3].
| Catalog Number | A000234 |
| CAS Number | 67-73-2 |
| Synonyms | (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one |
| Molecular Formula | C24H30F2O6 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1 |
| InChIKey | FEBLZLNTKCEFIT-VSXGLTOVSA-N |
| SMILES | CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)F)C |
| Reference | [1]. Nguyen L T H, et al. The potential of fluocinolone acetonide to mitigate inflammation and lipid accumulation in 2D and 3D foam cell cultures [J]. BioMed Research International, 2018, 2018. [2]. Liu Z, et al. Fluocinolone acetonide promotes the proliferation and mineralization of dental pulp cells [J]. Journal of endodontics, 2013, 39(2): 217-222. [3]. Cetinkaya-Fisgin A, et al. Identification of fluocinolone acetonide to prevent paclitaxel‐induced peripheral neuropathy [J]. Journal of the Peripheral Nervous System, 2016, 21(3): 128-133. [4]. Nehmé A, et al. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells [J]. BMC medical genomics, 2009, 2(1): 1-14. [5]. http://en.wikipedia.org/wiki/Fluocinolone_acetonide [6]. Nehme, A., et al., Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics, 2009. 2: p. 58. |
